Atherosclerosis Pipeline and Clinical Trials Assessment 2023: FDA Approvals, Therapies and Key Companies involved by DelveInsight | Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen

(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Atherosclerosis pipeline constitutes 25+ key companies continuously working towards developing 25+ Atherosclerosis treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

"Atherosclerosis Pipeline Insight, 2023" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Atherosclerosis Market.

The Atherosclerosis Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Some of the key takeaways from the Atherosclerosis Pipeline Report: https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Atherosclerosis treatment therapies with a considerable amount of success over the years.
• Atherosclerosis companies working in the treatment market are ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, CSL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others, are developing therapies for the Atherosclerosis treatment
• Emerging Atherosclerosis therapies in the different phases of clinical trials are- TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, and others are expected to have a significant impact on the Atherosclerosis market in the coming years.
• In December 2022, Amgen will initiate double-blind, randomized, placebo-controlled, multicenter studyassessing the impact of Olpasiran on major cardiovascular events in participants with Atherosclerotic CardiovascularDisease and Elevated Lipoprotein(a)

Atherosclerosis Overview
About 50% of deaths in westernised societies are attributable to atherosclerosis, a chronic inflammatory disease of the arteries.

Get a Free Sample PDF Report to know more about Atherosclerosis Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Emerging Atherosclerosis Drugs Under Different Phases of Clinical Development Include:
• TATX-21: ImmunoPrecise Antibodies
• Epeleuton: Afimmune
• VERVE-101: Verve Therapeutics
• SLN360: Silence Therapeutics
• MK-0616: Merck Sharp & Dohme LLC
• REG-001: Regio Bioscience
• Olpasiran: Amgen
• Ziltivekimab: Novo Nordisk
• CSL300: CSL Behring
• Inclisiran: Novartis Pharmaceuticals
• Ertugliflozin: Merck Sharp & Dohme LLC
• Olpasiran: Amgen
• Olezarsen: Ionis Pharmaceuticals, Inc.
• Obicetrapib: NewAmsterdam Pharma
• Tetrahydrobiopterin: BioMarin Pharmaceutical
• MEDI6570: AstraZeneca
• GFH312: Zhejiang Genfleet Therapeutics Co., Ltd.

Atherosclerosis Route of Administration
Atherosclerosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
• Oral
• Parenteral
• Intravenous
• Subcutaneous
• Topical.
• Molecule Type

Atherosclerosis Molecule Type
Atherosclerosis Products have been categorized under various Molecule types, such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type

Atherosclerosis Pipeline Therapeutics Assessment
• Atherosclerosis Assessment by Product Type
• Atherosclerosis By Stage and Product Type
• Atherosclerosis Assessment by Route of Administration
• Atherosclerosis By Stage and Route of Administration
• Atherosclerosis Assessment by Molecule Type
• Atherosclerosis by Stage and Molecule Type

DelveInsight's Atherosclerosis Report covers around 25+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Atherosclerosis product details are provided in the report. Download the Atherosclerosis pipeline report to learn more about the emerging Atherosclerosis therapies at:
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key companies in the Atherosclerosis Therapeutics Market include:
Key companies developing therapies for Atherosclerosis are - SL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others.

Atherosclerosis Pipeline Analysis:
The Atherosclerosis pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the treatment of Atherosclerosis with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Atherosclerosis Treatment.
• Atherosclerosis key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Atherosclerosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Atherosclerosis market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

Download Sample PDF Report to know more about Atherosclerosis drugs and therapies-
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Atherosclerosis Pipeline Market Drivers
• Rising prevalence of cardiovascular diseases, growing number of geriatric population, increase in the number of research and development activities are some of the important factors that are fueling the Atherosclerosis Market.

Atherosclerosis Pipeline Market Barriers
• However, high cost associated with the treatment, lack of awareness among people and other factors are creating obstacles in the Atherosclerosis Market growth.

Scope of Atherosclerosis Pipeline Drug Insight
• Coverage: Global
• Key Atherosclerosis Companies: ImmunoPrecise Antibodies, Afimmune, Verve Therapeutics, Silence Therapeutics, Merck Sharp & Dohme LLC, Regio Bioscience, Amgen, Novo Nordisk, CSL Behring, Novartis Pharmaceuticals, Merck Sharp & Dohme LLC, Amgen, Ionis Pharmaceuticals, Inc., NewAmsterdam Pharma, BioMarin Pharmaceutical, AstraZeneca, Zhejiang Genfleet Therapeutics Co., Ltd., and others
• Key Atherosclerosis Therapies: TATX-21, Epeleuton, VERVE-101, SLN360, MK-0616, REG-001, Olpasiran, Ziltivekimab, CSL300, Inclisiran, Ertugliflozin, Olpasiran, Olezarsen, Obicetrapib, Tetrahydrobiopterin, MEDI6570, GFH312, and others
• Atherosclerosis Therapeutic Assessment: Atherosclerosis current marketed and Atherosclerosis emerging therapies
• Atherosclerosis Market Dynamics: Atherosclerosis market drivers and Atherosclerosis market barriers

Request for Sample PDF Report for Atherosclerosis Pipeline Assessment and clinical trials-
https://www.delveinsight.com/sample-request/atherosclerosis-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. Atherosclerosis Report Introduction
2. Atherosclerosis Executive Summary
3. Atherosclerosis Overview
4. Atherosclerosis- Analytical Perspective In-depth Commercial Assessment
5. Atherosclerosis Pipeline Therapeutics
6. Atherosclerosis Late Stage Products (Phase II/III)
7. Atherosclerosis Mid Stage Products (Phase II)
8. Atherosclerosis Early Stage Products (Phase I)
9. Atherosclerosis Preclinical Stage Products
10. Atherosclerosis Therapeutics Assessment
11. Atherosclerosis Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Atherosclerosis Key Companies
14. Atherosclerosis Key Products
15. Atherosclerosis Unmet Needs
16 . Atherosclerosis Market Drivers and Barriers
17. Atherosclerosis Future Perspectives and Conclusion
18. Atherosclerosis Analyst Views
19. Appendix
20. About DelveInsight

Related Reports:

Atherosclerosis Market https://www.delveinsight.com/report-store/atherosclerosis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Atherosclerosis-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),

Latest Reports:

Multiple Myeloma Market https://www.delveinsight.com/report-store/multiple-myeloma-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Multiple Myeloma Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of multiple myeloma, historical and forecasted epidemiology as well as multiple myeloma market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Monkeypox Market https://www.delveinsight.com/report-store/monkeypox-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Monkeypox Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Monkeypox, historical and forecasted epidemiology as well as the Monkeypox market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Pars Planitis Market
https://www.delveinsight.com/report-store/pars-plantis-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Pars Plantis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Pars Plantis, historical and forecasted epidemiology as well as the Pars Plantis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Patient Monitoring Devices Market
https://www.delveinsight.com/report-store/patient-monitoring-devices-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Patient Monitoring Devices Market By Type Of Devices (Neuromonitoring Devices, Cardiac Monitoring Devices, Respiratory Monitoring Devices, Hemodynamic Monitoring Devices, Blood Glucose Monitoring Systems, And Others), By Application (Cardiology, Neurology, Respiratory, And Others), By End-User (Hospitals & Clinics, Ambulatory Surgical Centers, Home Care Settings, And Others), by geography, is anticipated to grow at a significant CAGR till 2028 owing to the growing prevalence of various chronic disorders and integration of advanced technology in the products

Typhoid Market https://www.delveinsight.com/report-store/typhoid-fever-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Typhoid Fever Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Typhoid Fever, historical and forecasted epidemiology as well as the Typhoid Fever market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Zika Virus Market https://www.delveinsight.com/report-store/zika-virus-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Zika Virus Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Zika Virus, historical and forecasted epidemiology as well as the Zika Virus market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Opioid Use Disorder Market https://www.delveinsight.com/report-store/opioid-use-disorder-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's "Opioid Use Disorder (OUD) - Market Insights, Epidemiology, and Market Forecast - 2032" report delivers an in-depth understanding of the Opioid Use Disorder (OUD), historical and forecasted epidemiology as well as the Opioid Use Disorder (OUD) market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Recent Blog's By DelveInsight:
• Insights Into The Cutaneous T-cell Lymphoma Treatment Market
https://www.delveinsight.com/blog/cutaneous-t-cell-lymphoma-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Roche's HEMLIBRA: A Game Changer in Hemophilia A Treatment Landscape
https://www.delveinsight.com/blog/hemlibra-for-hemophilia-a-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Emerging Role of Digital Health in the Field of Oncology
https://www.delveinsight.com/blog/digital-health-to-improve-cancer-management?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How Will Emerging Therapies Drift the Amyotrophic Lateral Sclerosis (ALS) Treatment Landscape
https://www.delveinsight.com/blog/evolving-als-treatment-landscape?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• How are Technological Trends and Innovations Reshaping the Dementia Care
https://www.delveinsight.com/blog/technological-innovations-in-dementia-care?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Assessing the Major Growth and Ongoing Developments in the Clinical Diagnostics Market
https://www.delveinsight.com/blog/clinical-diagnostics-market-outlook?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Non-opioid Analgesics Chronic Pain Treatment: Savior of Underserved Patients
https://www.delveinsight.com/blog/non-opioid-analgesics-for-chronic-pain-treatment?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Limited Availability and Lack of Access are Unlikely to Hinder the Billion-Dollar Alpha-1 Antitrypsin Deficiency (AATD) Treatment Market
https://www.delveinsight.com/blog/alpha-1-antitrypsin-deficiency-treatment-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr
• Evaluating the Key Trends and Technologies Shaping the Future of Dentistry https://www.delveinsight.com/blog/emerging-trends-in-dental-care-market?utm_source=blog&utm_medium=promotion&utm_campaign=gpr

Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
Healthcare Consulting
https://www.delveinsight.com/consulting-services

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

This release was published on openPR.